BUFORD, Ga.--(BUSINESS WIRE)--Theragenics Corporation® (NYSE: TGX), a medical device company serving the cancer treatment and surgical products markets, today announced it has executed a consulting agreement with Dr. Peter J. Fitzgerald to serve as its Chief Medical Director. Dr. Fitzgerald will advise the Company on research and product development, concentrating on cardiovascular and other opportunities within the Company’s surgical products segment. Dr. Fitzgerald is well known throughout the cardiovascular industry. He is currently the Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School. He is an Interventional Cardiologist and has a Ph.D. in engineering. He has led or participated in over 95 clinical trials, published over 300 manuscripts/chapters, and lectures worldwide.
